×
A Proposed Strategy for Management of Immunosuppression in Heart Transplant Patients wi...
https://doi.org/10.1111/ctr.14032
Clinical Transplantation; Ahluwalia M, Givertz MM et. al.

Jul 3rd, 2020 - There is limited experience in management of orthotopic heart transplant (OHT) patients with COVID-19. In this study, we present our initial experience using a standardized management algorithm. Data collection was performed on OHT patients with COVID-19 after March 10, 2020 (declaration of state-of-emergency in Massachusetts). Among the 358 OHT patients currently followed at our program, 5 pat...

Case reports study of the first five patients COVID-19 treated with remdesivir in France.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7326458
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases; Dubert M, Visseaux B et. al.

Jul 3rd, 2020 - The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been identified as responsible for the COVID-19 outbreak worldwide. Data on treatment are scare and parallels are made between SARS-CoV-2 and other coronavirus. Remdesivir is a broad spectrum antiviral with efficient in vitro activity against SARS-CoV-2 and controversial evidence of clinical improvement in severe COVID-19 pati...

Phylogenetic Analysis and Structural Perspectives of RNA-Dependent RNA-Polymerase Inhib...
https://doi.org/10.1007/s12539-020-00381-9
Interdisciplinary Sciences, Computational Life Sciences; Khan A, Khan M et. al.

Jul 2nd, 2020 - Most recently, an outbreak of severe pneumonia caused by the infection of SARS-CoV-2, a novel coronavirus first identified in Wuhan, China, imposes serious threats to public health. Upon infecting host cells, coronaviruses assemble a multi-subunit RNA-synthesis complex of viral non-structural proteins (nsp) responsible for the replication and transcription of the viral genome. Therefore, the ro...

World Takes Stock of COVID-19 Drug Remdesivir After US Snaps Up Supplies
https://www.medscape.com/viewarticle/933269

Jul 1st, 2020 - SEOUL/BERLIN/LONDON (Reuters) - Some governments in Europe and Asia said on Wednesday they have enough of Gilead's COVID-19 anti-viral remdesivir for now despite fears of shortages since the U.S. drugmaker pledged most output to its home market for the next three months. The pharmaceutical company's move stirred the global debate about equitable access to drugs and brought concerns about access...

COVID-19 and Remdesivir, Insulin Analogues, Opioid Use Disorder, Urinary Incontinence.
https://www.ncbi.nlm.nih.gov/pubmed/32603070
American Family Physician;

Jun 30th, 2020 - COVID-19 and Remdesivir, Insulin Analogues, Opioid Use Disorder, Urinary Incontinence.|2020||

UK COVID-19 Update: Better Local Data Needed, BMA Says
https://www.medscape.com/viewarticle/933239

Jun 30th, 2020 - These are the UK coronavirus stories you need to know about today. BMA: Better Local Data Needed The BMA says the Government needs to be more open and transparent with local COVID-19 data. The call came after criticism of the lack of timely local data in Leicester ahead of its lockdown. In its latest member tracker survey the BMA found more than 60% of doctors had little to no confidence in the...

COVID-19 Update: Pleading for PPE, Testing Surge Needed
https://www.medscape.com/viewarticle/933285

Jun 30th, 2020 - Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. Here are the coronavirus stories Medscape's editors around the globe think you need to know about today: AMA: Federal Help Needed With PPE for Physician Practices The American Medical Association (AMA) is asking the Trump administration to use the Defense Production Act to generate an adequate s...

Current pharmacological treatments for SARS-COV-2: A narrative review.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7320862
European Journal of Pharmacology; Nittari G, Pallotta G et. al.

Jun 30th, 2020 - The novel coronavirus, later identified as SARS-CoV-2, originating from Wuhan in China in November 2019, quickly spread around the world becoming a pandemic. Despite the knowledge of previous coronaviruses, such as those responsible for the SARS and MERS-CoV epidemic, there is no drug or prophylaxis treatment to this day. The rapid succession of scientific findings on SARS-CoV-2 provides a sign...

Scottish Firm to Trial T Cells as Possible COVID-19 Treatment
https://www.medscape.com/viewarticle/933197

Jun 30th, 2020 - LONDON (Reuters) - A Scottish biotechnology firm said on Tuesday it would start clinical trials on a possible T cell treatment for COVID-19, aimed at reducing the need for intensive care among hospitalised patients. T cells are white blood cells that form a key part of the immune system, along with antibodies, and scientists are hopeful they could play a role in tackling the novel coronavirus p...

Tocilizumab and Remdesivir in a Pregnant Patient With Coronavirus Disease 2019 (COVID-19).
https://doi.org/10.1097/AOG.0000000000004050
Obstetrics and Gynecology; Naqvi M, Zakowski P et. al.

Jun 29th, 2020 - There are limited data regarding treatment options for pregnant women with severe coronavirus disease 2019 (COVID-19). A 35-year-old primigravid patient at 22 weeks of gestation presented with 7 days of fever, cough, anosmia, and dyspnea. Nasopharyngeal swab was positive for the novel coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and a chest X-ray demonstrated bilate...

Hard-Hit US States 'Surge' Hospital Intensive Care Beds as ICU Wards Fill Up
https://www.medscape.com/viewarticle/933041

Jun 28th, 2020 - (Reuters) - Some Texas hospitals are running out of intensive care unit (ICU) beds for COVID-19 patients, turning to surge capacity that they expect will let them handle rising virus cases for another couple of weeks. Spikes of cases in several U.S. states including Texas, Arizona and Florida are raising concerns that the United States is relaxing lockdowns too fast and that hospitals may run o...

Gilead Prices COVID-19 Drug Candidate Remdesivir at $2,340 Per Patient
https://www.medscape.com/viewarticle/933097

Jun 28th, 2020 - (Reuters) - Gilead Sciences Inc has priced its COVID-19 drug candidate remdesivir at $2,340 for a five-day treatment in the United States and some other developed countries, potentially reflecting looming competition from a cheap steroid. The price tag is below the $5,080 per course recommendation by U.S. drug pricing research group, the Institute for Clinical and Economic Review (ICER), last w...

Covid-19: Remdesivir is recommended for authorisation by European Medicines Agency.
https://doi.org/10.1136/bmj.m2610
BMJ (Clinical Research Ed.); Wise J

Jun 28th, 2020 - Covid-19: Remdesivir is recommended for authorisation by European Medicines Agency.|2020|Wise J,|

COVID-19 Update: Stages to Brain Damage, Remdesivir Pricing
https://www.medscape.com/viewarticle/933151

Jun 28th, 2020 - Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. Here are the coronavirus stories Medscape's editors around the globe think you need to know about today: Stages to Brain Damage Neurologists propose a three-stage description of COVID-19's impact on the central nervous system in a new review, and they recommend hospitalized COVID-19 patients rec...

Key US Medical Group Adds Steroids to COVID-19 Treatment Guidelines
https://www.medscape.com/viewarticle/933055

Jun 28th, 2020 - (Reuters) - The Infectious Diseases Society of America (IDSA) has updated its treatment guidelines to include generic steroid pills for patients hospitalized with severe COVID-19. The only other drug the medical group recommends for COVID-19 patients outside of a clinical trial is remdesivir, the intravenous antiviral medication made by Gilead Sciences Inc. The IDSA late on Thursday said its ch...

Drug-induced liver injury in a COVID-19 patient: potential interaction of remdesivir wi...
https://doi.org/10.1093/cid/ciaa883
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America; Leegwater E, Strik A et. al.

Jun 27th, 2020 - We report a case of a male with COVID-19 who developed acute hepatotoxicity related to remdesivir with probable interaction of P-glycoprotein (P-gp) inhibitors. Until further details upon this interaction become available, we recommend physicians to be cautious with the prescription of P-gp inhibitors in patients receiving remdesivir therapy.

A COVID-19 pandemic guideline in evidence-based medicine.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7317259
Evidence-based Dentistry; Shamsoddin E

Jun 27th, 2020 - Data sources This review article scrutinised 16 clinical studies (clinical trials and observational studies) concerning coronavirus disease of 2019 (COVID-19). Additionally, 18 guidelines about the COVID-19 were reviewed and the key points were represented in this study.Study selection The review included human trials, in-vitro studies, review articles, and credible news reports about severe ac...

Safety, Tolerability, and Pharmacokinetics of Remdesivir, an Antiviral for Treatment of...
https://doi.org/10.1111/cts.12840
Clinical and Translational Science; Humeniuk R, Mathias A et. al.

Jun 26th, 2020 - Remdesivir (RDV), a single diastereomeric monophosphoroamidate prodrug that inhibits viral RNA polymerases, has potent in vitro antiviral activity against SARS-CoV2. RDV received FDA's emergency use authorization in United States and approval in Japan for treatment of severe COVID-19 patients. This report describes two phase 1 studies that evaluated the safety and pharmacokinetics (PK) of singl...

Remdesivir Receives Emergency Use Authorization for Severely Ill Patients with COVID-19.
https://doi.org/10.1097/01.NAJ.0000688196.83625.b1
The American Journal of Nursing; Aschenbrenner DS

Jun 26th, 2020 - Remdesivir Receives Emergency Use Authorization for Severely Ill Patients with COVID-19.|2020|Aschenbrenner DS,|

Gilead's Remdesivir Endorsed as First COVID-19 Treatment in Europe
https://www.medscape.com/viewarticle/932954

Jun 25th, 2020 - (Reuters) - The European healthcare regulator has recommended the conditional approval of Gilead Sciences Inc's antiviral treatment, remdesivir, for use in COVID-19 patients, making it the first treatment to be on track to be green-lit in the continent. The European Medicines Agency (EMA) said on Thursday its human medicines committee (CHMP) recommended the drug's use in adults and adolescents ...